Risk Factors for Large for Gestational Age (LGA) Births

Maternal Metabolic Factors

• Gestational diabetes mellitus (GDM) is the single most common risk factor for LGA, with maternal glucose concentration showing a continuum relationship with birth weight, according to the American Diabetes Association 1
• Maternal hyperglycemia creates an adverse intrauterine environment where excess glucose crosses the placenta, stimulating fetal insulin production and promoting excessive fetal growth and adiposity, as reported by the American Diabetes Association 1
• Pre-existing Type 1 diabetes mellitus significantly increases LGA risk, with undiagnosed and untreated GDM carrying up to 20% macrosomia risk, as stated by the American College of Obstetricians and Gynecologists 1
• Delivery past 38 weeks in GDM pregnancies leads to progressive macrosomia without reducing cesarean delivery rates, according to the American Diabetes Association 2

Maternal Weight and Weight Gain

• Pre-pregnancy overweight and obesity independently increase LGA risk, with very heavy women being nine times more likely to deliver LGA babies compared to average-weight women, as reported by the National Institute of Child Health and Human Development 3, 4
• Excessive gestational weight gain (exceeding IOM guidelines) is independently associated with higher LGA risk, particularly in obese women with GDM, according to the Institute of Medicine 3, 4

Maternal Physical Characteristics

• The combination of maternal prepregnancy BMI and height represents independent risk factors for large size at birth, as stated by the American Diabetes Association 1
• Maternal prepregnancy BMI operates through both genetic determinants and environmental components in utero, according to the American Diabetes Association 1

Genetic and Ethnic Factors

• Size at birth represents a complex interaction between maternal environment and fetal genes, as reported by the American Diabetes Association 1
• Genetic predisposition for type 2 diabetes and obesity may be inherited from one or both parents by offspring of GDM mothers, according to the American Diabetes Association 1
• Significant differences in screening eligibility exist between ethnic groups, as stated by the American Academy of Pediatrics 5

Pathophysiologic Mechanisms

• The intrauterine environment establishes programming of fetal development with lifelong health consequences through multiple mechanisms, including alterations of placental function, epigenetic modifications, increased inflammation, altered mitochondrial function, and maternal obesity-related dyslipidemia, as reported by the National Institute of Child Health and Human Development 3, 4
• Proposed mechanisms also include reduced energy expenditure and metabolic adaptation during pregnancy, according to the National Institute of Child Health and Human Development 3, 4

Fetal Adiposity

• Newborn infants of women with GDM have increased adiposity and reduced fat-free mass even when not macrosomic, as stated by the American Diabetes Association 1
• Measures of adiposity at birth may be more appropriate markers than traditional macrosomia definitions, according to the American Diabetes Association 1

Clinical Risk Stratification

• Screening for GDM with attention to first-trimester HbA1c ≥5.2% is associated with an increased risk of neonatal complications, as reported by the American College of Obstetricians and Gynecologists 6

Fetal Macrosomia Risk Factors in Gestational Diabetes Mellitus

Glycemic Control and Macrosomia Risk

• GDM of any severity increases macrosomia risk, not just poorly controlled cases, according to the American Diabetes Association 7
• Fasting hyperglycemia >105 mg/dL particularly increases risk of intrauterine fetal death in the last 4-8 weeks, as reported by the American Diabetes Association 7, 8

Maternal Gestational Hyperglycemia and Fetal Macrosomia: Evidence‑Based Facts

Definitions & Diagnostic Criteria

• Maternal gestational hyperglycemia (including gestational diabetes mellitus, GDM) is the primary driver of fetal macrosomia through fetal hyperinsulinemia 9.
• GDM is diagnosed when any of the following 75‑g oral glucose tolerance test values are met or exceeded: fasting ≥ 5.1 mmol/L (92 mg/dL), 1‑hour ≥ 10.0 mmol/L (180 mg/dL), or 2‑hour ≥ 8.5 mmol/L (153 mg/dL) 9.

Epidemiology

• GDM is typically identified at or after 24 weeks’ gestation, coinciding with the period of physiological insulin resistance that affects roughly 85 % of cases 10.
• In developed countries, GDM affects about 8.3 % of all pregnancies 10.

Pathophysiology

• The HAPO study demonstrated a graded, continuous relationship between increasing maternal glucose concentrations and the frequency of fetal macrosomia, with no clear glucose threshold—indicating that even mild hyperglycemia raises the risk 9.
• After delivery, fetal hyperinsulinemia can persist for 24–48 hours, while maternal glucose supply ceases immediately, creating a substantial risk of neonatal hypoglycemia 10.

Maternal Clinical Implications

• Pregnancies complicated by GDM carry higher rates of preeclampsia, cesarean delivery (odds ratio 1.4–4.3 depending on diabetes type), and postpartum hemorrhage 10.
• Recommended glycemic targets for GDM management are fasting < 5.2 mmol/L (95 mg/dL) and 2‑hour post‑prandial < 6.6 mmol/L (120 mg/dL) 10.

Neonatal Clinical Implications

• Infants of mothers with GDM have a 10–40 % prevalence of neonatal hypoglycemia, and are also at increased risk for hypocalcemia, hypomagnesemia, and polycythemia 10.
• These neonates experience higher rates of respiratory distress syndrome and NICU admission 10.

Summary Relationship

• GDM represents the maternal metabolic disease state, whereas fetal macrosomia is a major fetal complication arising from the hyperglycemia‑driven hyperinsulinemic cascade 9.